{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Amendment 2 (v2.1; 02 May 2019)', 'This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a)', 'of Directive 2001/20/EC of the European Parliament and the Council of the European Union', 'because it neither significantly impacts the safety or physical/mental integrity of participants nor', 'the scientific value of the study.', 'Overall Rationale for the Amendment:', 'The primary purpose of this amendment is to remove assessment of nitric oxide at the Screening', 'visit.', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 1.3 Schedule of Activities', 'Removed assessment of nitric', 'Nasal nitric oxide (nNO)', 'oxide at Screening visit.', 'and fractional exhaled nitric', 'oxide (FeNO) tests are not', 'required at the time of', 'screening.', 'Section 2.2 Background', 'Added results from a recent', 'Updated with results which', 'poster.', 'suggest that GB001', 'influences lung function in', 'subjects with markers of', 'eosinophilic inflammation.', 'Section 7.1 Discontinuation of', 'Included separate section on', 'Clarification on liver', 'Investigational Product', 'liver safety.', 'chemistry criteria that will', 'result in permanent', 'discontinuation of', 'investigational product.', 'Section 8.1.2 Computed Tomography', 'Updated text to imaging core', 'Clarification that imaging', '(CT)', 'laboratory.', 'core laboratory will analyze', 'CT sequences.', 'Section 10.3.5 Reporting of SAEs', 'Contact information was', 'Updated contact information', 'updated.', 'for sites outside North', 'America.', 'Global Change', 'Minor revisions to text.', 'Administrative updates were', 'incorporated, and', 'typographical errors were', 'corrected.', '87', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Amendment 1 (v2.0.0; 5 Apr 2019)', 'This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of', 'Directive 2001/20/EC of the European Parliament and the Council of the European Union based', 'on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and', 'the Council of the European Union.', 'Overall Rationale for the Amendment:', 'The primary purpose of this amendment is to increase the sample size of the study, include an', 'exclusion criterion for AERD, incorporate additional objectives and endpoints, and revise the', 'statistical considerations section to reflect the increased sample size and additional endpoints.', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 1.1 Synopsis;', 'Total sample size increased to', 'Increased total number of', 'Section 1.2 Schema;', '100. Added text on', 'subjects by 30 to enable', 'randomization and', 'better characterization of', 'Section 4.1.1 Study Design;', 'stratification.', 'benefit-risk profile in', 'Section 4.2.1 Study Population;', 'subjects with nasal polyps.', 'Section 6.3.1 Randomization;', 'Clarification on', 'Section 9 Statistical Considerations', 'randomization and', 'stratification.', 'Section 1.1 Synopsis;', 'Included additional secondary', 'Added and clarified', 'Section 1.3 Schedule of Activities;', 'endpoint and clarified', 'secondary endpoints to', 'Section 3 Objectives and Endpoints;', 'previous endpoints.', 'evaluate data including', 'exacerbations, time to first', 'Section 8.1.9 Other Assessments;', 'response in NPS, and change', 'Section 9.4.1.2 Secondary Efficacy', 'in total symptom score to', 'Analysis', 'better characterize CRS.', 'Section 1.3 Schedule of Activities', 'Hepatitis B surface antigen', 'Clarification to include', 'and Hepatitis C antibody text', 'indeterminate test result.', 'was updated.', 'Section 1.3 Schedule of Activities;', 'Added use of mometasone', 'MFNS may not be available', 'Section 4.1.1 Study Design;', 'furoate nasal spray (MFNS)', 'in some ex-US countries and', 'Section 4.2.1 Study Population;', 'equivalent.', 'therefore an equivalent', 'product may be used.', 'Section 5.3 Randomization Criteria;', 'Section 8 Study Assessments and', 'Procedures', 'Section 3 Objectives and Endpoints', 'Included additional', 'Added 3 exploratory', 'exploratory endpoints.', 'endpoints to further', 'understand the role of', 'GB001 in CRS.', 'Section 4.1.1 Study Design', 'Written informed consent text', 'The modification was made', 'was updated.', 'to clarify that informed', 'consent may be obtained', 'prior to Visit 1 to allow for', 'medication washouts and', '88', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}